MedTrace Logo

Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers

NCT04948866 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 884

Last updated 2025-12-16

Study results available
· View outcomes & findings →

Summary

Millions of Americans have late-stage Alzheimer's and related dementias (ADRD), causing suffering due to loss of awareness of self and family, progressive dependency, physical and neuropsychiatric symptoms, and physical, emotional and financial strain for caregivers. Investigators now propose a multi-site randomized clinical trial of the ADRD Palliative Care (ADRD-PC) program for persons with late-stage ADRD and their family caregivers, triggered during hospitalization. Investigators aim to learn if this program of dementia-specific palliative care, standardized caregiver education, and transitional care is effective to reduce burdensome hospital transfers, improve symptom treatment and control, augment supportive services, and reduce nursing home transitions for patients, and to improve caregiver outcomes of communication, shared decision-making and distress.

Conditions

  • Dementia
  • Dementia, Vascular
  • Dementia With Lewy Bodies
  • Dementia Frontal
  • Dementia, Mixed
  • Dementia Alzheimers
  • Alzheimer Disease
  • Dementia Severe

Interventions

BEHAVIORAL

ADRD-PC Program

Included in arm/group descriptions

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Laura C Hanson, MD, MPH · University of North Carolina

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2025-02-01
Completion
2025-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948866 on ClinicalTrials.gov